BioMedNewsBreaks

MondayAug 24, 2026 12:05 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration

VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (“AOCs”) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies’ technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells. The companies said they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. To view the full press release, visit https://ibn.fm/IF9Cy About VERAXA Biotech AG (NASDAQ:…

Continue Reading

FridayAug 21, 2026 3:30 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the…

Continue Reading

ThursdayAug 20, 2026 10:49 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) entered into a non-binding letter of intent (“LOI”) with Ifowonco Informatics Incorporated as an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (“LAG-3”). The proposed collaboration is intended to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (“DDR”) therapeutics, translational oncology and clinical development, with the companies believing the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. Ifowonco’s program is…

Continue Reading

WednesdayAug 19, 2026 1:04 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS around the idea that multiple sclerosis disability can progress independently of relapses, known as progression independent of relapse activity (“PIRA”). A recent article discusses chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing tissue damage that may not be adequately addressed by therapies focused primarily on peripheral immune activity. Lucid-MS takes a different approach by targeting myelin degradation, with the goal of preserving myelin and supporting functional recovery rather than broadly…

Continue Reading

WednesdayAug 19, 2026 10:55 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Acquires Zoolzy to Expand Pharmaceutical Supply Chain and Veterinary Market Reach

Earth Science Tech (OTC: ETST), a strategic holding company focused on a diversified portfolio, announced the acquisition of Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products. Operating from a 3,684-square-foot facility, Zoolzy is expected to integrate into ETST’s supply chain and enable its compounding pharmacies to procure APIs at competitive wholesale pricing, which the company says could increase overall profit margins. The acquisition also broadens ETST’s access to novel APIs for custom compounding and provides immediate procurement access to common veterinary medications. ETST plans to leverage the new supply line to…

Continue Reading

TuesdayAug 18, 2026 1:54 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This followed a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents. Regentis’ proprietary manufacturing process increases yield fivefold, simplifies production and is built to support commercial-scale manufacturing—important advantages for an off-the-shelf cartilage-repair product designed to avoid the complexity and cost of cell-based procedures. The milestone comes as the company…

Continue Reading

TuesdayAug 18, 2026 12:59 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology

VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused research organization Ardigen could strengthen the company’s oncology pipeline as artificial intelligence plays an increasingly important role in drug discovery. By combining Ardigen’s expertise in AI, computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform, the companies aim to use AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while improving target validation and reducing development risks. VERAXA’s “AND-gated” approach, which activates therapies only when two cancer-associated targets are present on the same cell, may be particularly well suited to AI-driven analysis…

Continue Reading

TuesdayAug 18, 2026 11:18 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Exclusive UK Reseller Agreement for HealthOST AI Bone Solution

Nanox (NASDAQ: NNOX) , a leader in innovative medical imaging technology, announced that subsidiary Nanox AI Ltd. entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term. HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans to support clinicians in evaluating and assessing musculoskeletal disease of the spine, including osteoporosis. In November 2025, the National Institute for Health and Care Excellence (“NICE”) recommended HealthOST and a previous version, HealthVCF, among five AI technologies for National Health Service (“NHS”)…

Continue Reading

MondayAug 17, 2026 1:55 pm

BioMedNewsBreaks — Dyadic International, Inc. (NASDAQ: DYAI) Entered Agreements for $2.9 Million Registered Direct Offering and Private Placement 

Dyadic International (NASDAQ: DYAI) doing business as Dyadic Applied BioSolutions, entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase 3,625,000 common shares. The common shares are priced at $0.795 each and the warrants at $0.005 each, with the warrants carrying an exercise price of $0.84 per share. Aggregate gross proceeds are expected to be approximately $2.9 million. The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, together with existing cash, cash equivalents,…

Continue Reading

FridayAug 14, 2026 3:07 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Builds Foundation for Biomarker-Driven Cancer Therapy

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and metabolism studies through Nucro-Technics as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010’s metabolic profile and generate data for future pharmacokinetic, toxicology and regulatory activities. By combining targeted PNKP inhibition, nanoparticle…

Continue Reading